| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7214695 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Dec, 2024
(7 months from now) | |
| US9770441 | FOLDRX PHARMS | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole |
Aug, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214696 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Dec, 2024
(7 months from now) | |
Vyndamax is owned by Foldrx Pharms.
Vyndamax contains Tafamidis.
Vyndamax has a total of 3 drug patents out of which 0 drug patents have expired.
Vyndamax was authorised for market use on 03 May, 2019.
Vyndamax is available in capsule;oral dosage forms.
Vyndamax can be used as treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm).
Drug patent challenges can be filed against Vyndamax from 04 May, 2023.
The generics of Vyndamax are possible to be released after 31 August, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 03, 2024 |
| Orphan Drug Exclusivity(ODE-237) | May 03, 2026 |
Drugs and Companies using TAFAMIDIS ingredient
NCE-1 date: 04 May, 2023
Market Authorisation Date: 03 May, 2019
Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)
Dosage: CAPSULE;ORAL
VYNDAMAX family patents
